Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Celyad Oncology (CYAD) NPV

Sell:€3.90 Buy:€4.06 Change: €0.075 (1.88%)
Market closed |  Prices as at close on 26 July 2021 | Switch to live prices |
Change: €0.075 (1.88%)
Market closed |  Prices as at close on 26 July 2021 | Switch to live prices |
Change: €0.075 (1.88%)
Market closed |  Prices as at close on 26 July 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Celyad Oncology SA, formerly Celyad SA is a Belgium-based company. The Company is a clinical-stage biotechnology company focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company develops allogeneic and autologous CAR T cell therapy candidates for cancer patients with hematological malignancies and solid tumors. The Company's product, CYAD-101 is a NKG2D receptor-based CAR T, which incorporates non-gene edited allogeneic TIM technology, for the treatment of refractory metastatic colorectal cancer (mCRC). It also develops short hairpin RNA (shRNA)-based allogeneic CAR T candidate CYAD-211 for the treatment of relapsed or refractory multiple myeloma (r/r MM). Its autologous CAR T franchise is evaluating NKG2D receptor CAR T candidate CYAD-02 for the treatment of relapsed or refractory acute myeloid leukemia (r/r AML) and myelodysplastic syndromes (MDS).

Contact details

Axis Business Park Rue Edouard Belin 2
+32 (10) 394100

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
€61.98 million
Shares in issue:
15.49 million
Euronext Brussels

Key personnel

  • Michel Lussier
    Chairman of the Board, Co-Founder
  • Filippo Petti
    Chief Executive Officer, Chief Financial Officer, Director
  • Gaetane Metz
    Chief Operating Officer
  • Carri Duncan
    Vice President Corporate Development and Communications
  • Anne Moore
    Vice President Corporate Strategy
  • Richard Mountfield
    Vice President of Global Regulatory Affairs
  • Peter De Waele
    Member of the Executive Management Committee, Vice President - Research & Development
  • Georges Rawadi
    Vice President - Business Development
  • Seron Aymeric
    Program Manager
  • Philippe Dechamps
    Chief Legal Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.